Aura Biosciences, Inc. (AURA)
7.185
-0.18
(-2.38%)
USD |
NASDAQ |
Sep 09, 16:00
7.185
0.00 (0.00%)
After-Hours: 17:45
Aura Biosciences Enterprise Value : 454.37M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 454.37M |
| September 04, 2026 | 475.06M |
| September 03, 2026 | 455.40M |
| September 02, 2026 | 468.85M |
| September 01, 2026 | 461.61M |
| August 31, 2026 | 435.74M |
| August 28, 2026 | 458.51M |
| August 27, 2026 | 489.55M |
| August 26, 2026 | 492.66M |
| August 25, 2026 | 501.97M |
| August 24, 2026 | 510.25M |
| August 21, 2026 | 499.90M |
| August 20, 2026 | 496.79M |
| August 19, 2026 | 498.86M |
| August 18, 2026 | 537.15M |
| August 17, 2026 | 487.48M |
| August 14, 2026 | 488.52M |
| August 13, 2026 | 484.38M |
| August 12, 2026 | 494.72M |
| August 11, 2026 | 524.73M |
| August 10, 2026 | 489.55M |
| August 07, 2026 | 519.56M |
| August 06, 2026 | 491.62M |
| August 05, 2026 | 435.74M |
| August 04, 2026 | 432.64M |
| Date | Value |
|---|---|
| August 03, 2026 | 421.25M |
| July 31, 2026 | 418.15M |
| July 30, 2026 | 428.50M |
| July 29, 2026 | 418.15M |
| July 28, 2026 | 422.29M |
| July 27, 2026 | 433.67M |
| July 24, 2026 | 422.29M |
| July 23, 2026 | 437.81M |
| July 22, 2026 | 418.15M |
| July 21, 2026 | 420.22M |
| July 20, 2026 | 398.49M |
| July 17, 2026 | 416.08M |
| July 16, 2026 | 405.73M |
| July 15, 2026 | 418.15M |
| July 14, 2026 | 417.11M |
| July 13, 2026 | 417.11M |
| July 10, 2026 | 400.56M |
| July 09, 2026 | 417.11M |
| July 08, 2026 | 442.98M |
| July 07, 2026 | 420.22M |
| July 06, 2026 | 426.43M |
| July 02, 2026 | 493.69M |
| July 01, 2026 | 389.18M |
| June 30, 2026 | 427.46M |
| June 29, 2026 | 343.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
| Sarepta Therapeutics, Inc. | 2.469B |
| Anixa Biosciences, Inc. | 83.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.64M |
| Total Expenses (Quarterly) | 45.64M |
| EPS Diluted (Quarterly) | -0.4811 |
| Earnings Yield | -24.76% |
| Normalized Earnings Yield | -24.76 |